Telmisartan pharmacokinetics in Japanese renal transplant recipients

Clinica Chimica Acta

Volumn 399, Issue 1-2, 2009, Pages 83-87

  Miura, Masatomo ^a   Satoh, Shigeru ^b   Inoue, Kazuyuki ^a   Saito, Mitsuru ^b   Habuchi, Tomonori ^b   Suzuki, Toshio ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

MRP2; OATP; Pharmacokinetics; Telmisartan; UGT

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CANDESARTAN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN ABCC2; PROTEIN SLCO 1B1; PROTEIN SLCO 1B3; PROTEIN SLCO 2B1; TELMISARTAN; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCC2 GENE; ABCG2 GENE; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; KIDNEY GRAFT; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RECIPIENT; SLCO 1B1 GENE; SLCO 1B3 GENE; SLCO 2B1 GENE; UGT 1A1 GENE; UGT 1A6 GENE; UGT 1A7 GENE; UGT 1A9 GENE; UGT 2B7 GENE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; BENZIMIDAZOLES; BENZOATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; JAPAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TIME FACTORS; YOUNG ADULT;

EID: 57049170781     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.09.020     Document Type: Article

References (35)

1. Cantarovich F., and Rangoonwala B. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease. Int J Clin Pract 57 (2003) 801-822
2. Stangier J., Su C.A., Schondorfer G., and Roth W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 40 (2000) 1355-1364
3. 14C] telmisartan in healthy volunteers. J Clin Pharmacol 40 (2000) 1312-1322
4. Konig J., Seithel A., Gradhand U., and Fromm M.F. Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg's Arch Pharmacol 372 (2006) 432-443
5. Konig J., Cui Y., Nies A.T., and Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278 (2000) G156-G164
6. Konig J., Cui Y., Nies A.T., and Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275 (2000) 23161-23168
7. Briz O., Serrano M.A., Maclas R.I., Gonzalez-Gallego J., and Marin J.J. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 371 (2003) 897-905
8. Kullak-Ublick G.A., Ismair M.G., Stieger B., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120 (2001) 525-533
9. Kobayashi D., Nozawa T., Imai K., Nezu J., Tsuji A., and Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306 (2003) 703-708
10. Schaub T.P., Kartenbeck J., Konig J., et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10 (1999) 1159-1169
11. Matsushima S., Maeda K., Kondo C., et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314 (2005) 1059-1067
12. Ishiguro N., Maeda K., Kishimoto W., et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34 (2006) 1109-1115
13. Ishiguro N., Maeda K., Saito A., et al. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 36 (2008) 796-805
14. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60 (2000) 6921-6926
15. Yamanaka H., Nakajima M., Hara Y., et al. Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. Drug Metab Pharmacokinet 20 (2005) 135-143
16. Verlaan M., Drenth J.P., and Truninger K. Polymorphisms of UDP-glucuronosyltransferase 1A7 are not involved in pancreatic diseases. J Med Genet 42 (2005) e62
17. van der Logt E.M., Bergevoet S.M., Roelofs H.M., et al. Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis 25 (2004) 2407-2415
18. Girard H., Villeneuve L., Court M.H., et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 34 (2006) 1220-1228
19. Nozawa T., Nakajima M., Tamai I., et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302 (2002) 804-813
20. Tsujimoto M., Hirata S., Dan Y., Ohtani H., and Sawada Y. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab Pharmacokinet 21 (2006) 165-169
21. Cascorbi I., Gerloff T., Johne A., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69 (2001) 169-174
22. Naesens M., Kuypers D.R., Verbeke K., and Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82 (2006) 1074-1084
23. Rau T., Erney B., Gores R., Eschenhagen T., Beck J., and Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 80 (2006) 468-476
24. Kobayashi D., Ieiri I., Hirota T., et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33 (2005) 94-101
25. Ogihara T., Minami F., Kainuma H., et al. Pharmacokinetic evaluation of an angiotensin II AT1 receptor antagonist BIBR277 (temisartan) in hypertensive patients. Jpn Pharmacol Ther 30 (2002) S-271-S-283
26. Benndorf R.A., Rudolph T., Appel D., et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55 (2006) 1159-1164
27. Pershadsingh H.A., and Kurtz T.W. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 27 (2004) 1015
28. Miura Y., Yamamoto N., Tsunekawa S., et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28 (2005) 757-758
29. Strassburg C.P., Oldhafer K., Manns M.P., and Tukey R.H. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52 (1997) 212-220
30. Tukey R.H., and Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40 (2000) 581-616
31. Fisher M.B., Paine M.F., Strelevitz T.J., and Wrighton S.A. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33 (2001) 273-297
32. Kobayashi M., Saitoh H., Kobayashi M., Tadano K., Takahashi Y., and Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309 (2004) 1029-1035
33. van Hest R.M., van Gelder T., Vulto A.G., and Mathot R.A. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 44 (2005) 1083-1096
34. Miura M., Satoh S., Inoue K., et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63 (2007) 1161-1169
35. Miura M, Kagaya H, Satoh S, et al. Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients. Ther Drug Monit 2008; In press.